Εμφανίζονται 1 - 16 Αποτελέσματα από 16 για την αναζήτηση '"ПРОТОЧНАЯ ЦИТОФЛУОРОМЕТРИЯ"', χρόνος αναζήτησης: 0,54δλ Περιορισμός αποτελεσμάτων
  1. 1
    Academic Journal

    Πηγή: Drug development & registration; Том 10, № 4 (2021): Приложение 1; 14-19 ; Разработка и регистрация лекарственных средств; Том 10, № 4 (2021): Приложение 1; 14-19 ; 2658-5049 ; 2305-2066

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.pharmjournal.ru/jour/article/view/1096/906; https://www.pharmjournal.ru/jour/article/view/1096/932; https://www.pharmjournal.ru/jour/article/downloadSuppFile/1096/928; Newman D. J., Cragg G. M. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. Journal of natural products. 2020;83(3):770–803. DOI:10.1021/acs.jnatprod.9b01285.; Al-Ani F., Chehade S., Lazo-Langner A. Thrombosis risk associated with COVID-19 infection. A scoping review. Thrombosis research. 2020;1(192):152–160. DOI:10.1016/j.thromres.2020.05.039.; Tsoupras A., Lordan R., Zabetakis I. Thrombosis and COVID-19: The Potential role of nutrition. Frontiers in Nutrition. 2020;7:177. DOI:10.3389/fnut.2020.583080.; Громов А. А., Кручинина М. В., Рабко А. В. Коронавирусная болезнь COVID-19: неиспользованные возможности терапии. Русский медицинский журнал. 2020;28(9):2–6.; Nignpense E. B., Chinkwo K. A., Blanchard C. L., Santhakumar A. B. Polyphenols: modulators of platelet function and platelet microparticle generation? International journal of molecular sciences. 2020;21(1):146. DOI:10.3390/ijms21010146.; Olas B. A review of in vitro studies of the anti-platelet potential of citrus fruit flavonoids. Food and Chemical Toxicology. 2021:112090. DOI:10.1016/j.fct.2021.112090.; Ивкин Д. Ю., Лужанин В. Г., Карпов А. А., Минасян С. М., Полещенко Я. И., Мамедов А. Э., Повыдыш М. Н., Поройков В. В., Наркевич И. А. Эмбинин-перспективное кардиотоническое средство природного происхождения. Разработка и регистрация лекарственных средств. 2018;3:166–170.; Liguori I., Russo G., Curcio F., Bulli G., Aran L., Della-Morte D., Gargiulo G., Testa G., Cacciatore F., Bonaduce D., Abete P. Oxidative stress, aging, and diseases. Clinical interventions in aging. 2018;13:757. DOI:10.2147/CIA.S158513.; Peoples J. N., Saraf A., Ghazal N., Pham T. T., Kwong J. Q. Mitochondrial dysfunction and oxidative stress in heart disease. Experimental & molecular medicine. 2019;51(12):1–3. DOI:10.1038/s12276-019-0355-7.; Steven S., Frenis K., Oelze M., Kalinovic S., Kuntic M., Bayo Jimenez M. T., Vujacic-Mirski K., Helmstädter J., Kröller-Schön S., Münzel T., Daiber A. Vascular inflammation and oxidative stress: major triggers for cardiovascular disease. Oxidative medicine and cellular longevity. 2019:1–26. DOI:10.1155/2019/7092151.; Panche A. N., Diwan A. D., Chandra S. R. Flavonoids: an overview. Journal of Nutritional Science. 2016:5. DOI:10.1017/jns.2016.41.; Cheng Y., Xia Z., Han Y., Rong J. Plant natural product formononetin protects rat cardiomyocyte H9c2 cells against oxygen glucose deprivation and reoxygenation via inhibiting ROS formation and promoting GSK-3β phosphorylation. Oxidative medicine and cellular longevity. 2016:1–11. DOI:10.1155/2016/2060874.; Huang Z., Liu Y., Huang X. Formononetin may protect aged hearts from ischemia/reperfusion damage by enhancing autophagic degradation. Molecular Medicine Reports. 2018;18(6):4821–4830. DOI:10.3892/mmr.2018.9544.; Li T., Zhong Y., Tang T., Luo J., Cui H., Fan R., Wang Y., Wang D. Formononetin induces vasorelaxation in rat thoracic aorta via regulation of the PI3K/PTEN/Akt signaling pathway. Drug design, development and therapy. 2018;12:3675. DOI:10.2147/DDDT.S180837.; Zhu H., Zou L., Tian J., Lin F., He J., Hou J. Protective effects of sulphonated formononetin in a rat model of cerebral ischemia and reperfusion injury. Planta medica. 2014;80(04):262–268. DOI:10.1055/s-0033-1360340.; Зверев Я. Ф. Антитромбоцитарная активность флавоноидов. Вопросы питания. 2017;86(6):6–20.; Лужанин, В. Г., Уэйли, А. К., Понкратова, А. О., Гришукова Е. А., Сулоев, И. С., Смирнов, С. Н., Серебряков, Е. Б. Выделение индивидуальных соединений из надземной части стальника полевого (Ononis arvensis L.) и золотарника канадского (Solidago canadensis L.). Разработка и регистрация лекарственных средств. 2021;10(1):83–89. DOI:10.33380/2305-2066-2021-10-1-83-89.; https://www.pharmjournal.ru/jour/article/view/1096

  2. 2
    Academic Journal

    Πηγή: Rheumatology Science and Practice; Vol 56, No 6 (2018); 731-738 ; Научно-практическая ревматология; Vol 56, No 6 (2018); 731-738 ; 1995-4492 ; 1995-4484

    Περιγραφή αρχείου: application/pdf

    Relation: https://rsp.mediar-press.net/rsp/article/view/2650/1780; Насонов ЕЛ. Проблемы иммунопатологии ревматоидного артрита: эволюция болезни. Научно-практическая ревматология. 2017;55(3):277-94 [Nasonov EL. Рroblems of rheumatoid arthritis immunopathology: evolution of the disease. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(3):277-94 (In Russ.)]. doi:10.14412/1995-4484-2017-277-294; Leslie D, Lipsky P, Notkins AL. Autoantibodies as predictors of disease. J Clin Invest. 2001;108:1417-22. doi:10.1172/JCI14452; Leandro M. B cells and rheumatoid factors in autoimmunity. Int J Rheum Dis. 2015;18:379-81. doi:10.1111/1756-185X.12690; Lino AC, Dorner T, Bar-Or A, Fillatreau S. Cytokine-producing B cells: a translational view on their roles in human and mouse autoimmune diseases. Immunol Rev. 2016;269:130-44. doi:10.1111/imr.12374; Насонов ЕЛ, Лила АМ. Ингибиция интерлейкина 6 при иммуновоспалительных ревматических заболеваниях: достижения, перспективы и надежды. Научно-практическая ревматология. 2017;55(6):590-9 [Nasonov EL, Lila AM. Inhibition of interleukin 6 in immune inflammatory rheumatic diseases: achievements, prospects, and hopes. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(6):590-9 (In Russ.)]. doi:10.14412/1995-4484-2017-590-599; Scott LJ. Tocilizumab: A Review in Rheumatoid Arthritis. Drugs. 2017 Nov;77(17):1865-79. doi:10.1007/s40265-017-0829-7; Yeo L, Toellner KM, Salmon M, et al. Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis. Ann Rheum Dis. 2011 Nov;70(11):2022-8. doi:10.1136/ard.2011.153312; Mihara M, Hashizume M, Yoshida H, et al. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond). 2012 Feb;122(4):143-59. doi:10.1042/CS20110340; Burmester GR, Feist E, Dö rner T. Emerging cell and cytokine targets in rheumatoid arthritis. Nat Rev Rheumatol. 2014 Feb;10(2):77-88. doi:10.1038/nrrheum.2013.168; Roll P, Muhammad K, Schumann M, et al. In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment. Arthritis Rheum. 2011 May;63(5):1255-64. doi:10.1002/art.30242; Moura RA, Quaresma C, Vieira AR, et al. B-cell phenotype and IgD-CD27- memory B cells are affected by TNF-inhibitors and tocilizumab treatment in rheumatoid arthritis. PLoS One. 2017 Sep 8;12(9):e0182927. doi:10.1371/journal.pone.0182927; Lubbers J, Vosslamber S, van de Stadt LA, et al. B cell signature contributes to the prediction of RA development in patients with arthralgia. Ann Rheum Dis. 2015;74:1786-8. doi:10.1136/annrheumdis-2015-207324; Van Baarsen LGM, de Hair MJH, Ramwadhdoebe TH, et al. The cellular composition of lymph nodes in the earliest phase of inflammatory arthritis. Ann Rheum Dis. 2013;72:1420-4. doi:10.1136/annrheumdis-2012-202990; Amara K, Steen J, Murray F, et al. Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition. J Exp Med. 2013;210:445-55. doi:10.1084/jem.20121486; Li S, Yu Y, Yue Y, et al. Autoantibodies from single circulating plasmablasts react with citrullinated antigens and Porphyromonas gingivalis in rheumatoid arthritis. Arthritis Rheum. 2016;68:614-26. doi:10.1002/art.39455; Muhammad K, Roll P, Einsele H, et al. Delayed acquisition of somatic hypermutations in repopulated IGD+CD27+ memory B cell receptors after rituximab treatment. Arthritis Rheum. 2009;60:2284-93. doi:10.1002/art.24722; Adlowitz DG, Barnard J, Biear J, et al. Expansion of Activated Peripheral Blood Memory B Cells in Rheumatoid Arthritis, Impact of B Cell Depletion Therapy, and Biomarkers of Response. PLoS One. 2015 Jun 5;10(6):e0128269. doi:10.1371/journal.pone.0128269; Fekete A, Soos L, Szekanecz Z, et al. Disturbances in B- and T-cell homeostasis in rheumatoid arthritis: suggested relationships with antigen-driven immune responses. J Autoimmun. 2007;29:154-63. doi:10.1016/j.jaut.2007.07.002; Moura RA, Graca L, Fonseca JE. To B or not to B the conductor of rheumatoid arthritis orchestra. Clin Rev Allergy Immunol. 2012 Dec;43(3):281-91. doi:10.1007/s12016-012-8318-y; Супоницкая ЕВ, Алексанкин АП, Александрова ЕН и др. Определение субпопуляций В-лимфоцитов периферической крови методом проточной цитофлуорометрии у здоровых лиц и больных ревматическими заболеваниями. Клиническая лабораторная диагностика. 2015;60(6):30-33 [Suponitskaya EV, Aleksankin AP, Alexandrova EN, et al. Characterization of peripheral blood b-cell subset in patients with systemic lupus erythematosus. Klinicheskaya Laboratornaya Diagnostika. 2015;60(6):30-3 (In Russ.)].; Nakayamada S, Kubo S, Yoshikawa M, et al. Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis. Rheumatology (Oxford). 2018 Jan 1;57(1):164-74. doi:10.1093/rheumatology/kex012; Lü bbers J, van Beers-Tas MH, Vosslamber S, et al. Changes in peripheral blood lymphocyte subsets during arthritis development in arthralgia patients. Arthritis Res Ther. 2016;18(1):205. doi:10.1186/s13075-016-1102-2; Moura RA, Weinmann P, Pereira PA, et al. Alterations on peripheral blood B-cell subpopulations in very early arthritis patients. Rheumatology (Oxford). 2010;49:1082-92. doi:10.1093/rheumatology/keq029; Mahmood Z, Muhammad K, Schmalzing M, et al. CD27-IgDmemory B cells are modulated by in vivo interleukin-6 receptor (IL-6R) blockade in rheumatoid arthritis. Arthritis Res Ther. 2015 Mar 14;17:61. doi:10.1186/s13075-015-0580-y; Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010;62:542-52. doi:10.1002/art.27221; Меснянкина АА, Соловьев СК, Александрова ЕН и др. Динамика субпопуляции В-лимфоцитов у больных системной красной волчанкой на фоне терапии генно-инженерными биологическими препаратами. Научно-практическая ревматология. 2017;55(3):252-60 [Mesnyankina AA, Solovyev SK, Aleksandrova EN, et al. The time course of changes in B lymphocyte subpopulations in patients with systemic lupus erythematosus during therapy with biological agents. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(3):252-60 (In Russ.)]. doi:10.14412/1995-4484-2017-252-260; Marie-Cardine A, Divay F, Dutot I, et al. Transitional B cells in humans: characterization and insight from B lymphocyte reconstitution after hematopoietic stem cell transplantation. Clin Immunol. 2008;127:14-25. doi:10.1016/j.clim.2007.11.013; Fonseca JE, Santos MJ, Canhao H, Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev. 2009;8:538-42. doi:10.1016/j.autrev.2009.01.012; Jourdan M, Cren M, Robert N, et al. IL-6 supports the generation of human long-lived plasma cells in combination with either APRIL or stromal cell-soluble factors. Leukemia. 2014 Aug;28(8):1647-56. doi:10.1038/leu.2014.61; Muhammad K, Roll P, Seibold T, et al. Impact of IL-6 receptor inhibition on human memory B cells in vivo: impaired somatic hypermutation in preswitch memory B cells and modulation of mutational targeting in memory B cells. Ann Rheum Dis. 2011;70:1507-10. doi:10.1136/ard.2010.141325; Kikuchi J, Hashizume M, Kaneko Y, et al. Peripheral blood CD4(+)CD25(+)CD127(low) regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response. Arthritis Res Ther. 2015 Jan 21;17:10. doi:10.1186/s13075-015-0526-4; Fleischer S, Ries S, Shen P, et al. Anti-interleukin-6 signalling therapy rebalances the disrupted cytokine production of B cells from patients with active rheumatoid arthritis. Eur J Immunol. 2018 Jan;48(1):194-203. doi:10.1002/eji.201747191; Alivernini S, Kurowska-Stolarska M, Tolusso B, et al. MicroRNA-155 influences B-cell function through PU.1 in rheumatoid arthritis. Nat Commun. 2016 Sep 27;7:12970. doi:10.1038/ncomms12970; Wu Y, El Shikh ME, El Sayed RM, et al. IL-6 produced by immune complex-activated follicular dendritic cells promotes germinal center reactions, IgG responses and somatic hypermutation. Int Immunol. 2009;21:745-56. doi:10.1093/intimm/dxp041

  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16